AUG 2017

InterAx welcomes Prof. Dr. Michel Bouvier as new Advisory Board Member


August 2017, Switzerland-Canada


Scientific advisory boards set the bar for the quality of research and development performed in big pharma, medium biotech and small start-ups. Their excellence is a measure for scientific standards and innovation in an enterprise. They provide insights into scientific trends from an international perspective, give strategic advice for the company’s R&D plans and consolidate technological leadership. InterAx Biotech AG, a spin-off of the Paul Scherrer Institute (PSI), has strengthened its scientific advisory board with one of the most internationally cited scientists, Prof. Michel Bouvier from the University of Montréal.

Professor Bouvier is Chief Executive Officer of the Institute for Research in Immunology and Cancer (IRIC) and professor in the Department of Biochemistry and Molecular Medicine at the Faculty of Medicine of the University of Montreal. His research focuses on deciphering the molecular mechanisms that regulate one of the most important classes of current drug targets, the family of G protein-coupled receptors (GPCRs). Many of his groundbreaking findings have over the years led to significant paradigm shifts in the field and paved the way for alternative strategies to develop novel and safer drugs targeting GPCRs. In his role as a scientific advisor, he will advise InterAx Biotech in the development of the company’s proprietary novel biosensors. These biosensors are the core pillar of the InterAx GPCR lead discovery platform that combines biosensors with Computational Biology for quantitative comparison of drug-induced GPCR signaling. InterAx unique drug discovery platform will dramatically reduce costs for the development of novel GPCR drugs with reduced side effects, thereby benefiting patients with unmet medical needs.

In his Interview to PARK INNOVAARE, Professor Bouvier explains what caught his interest in this Swiss start-up and how he sees its development in years to come.

PARK INNOVAARE: Why did you decide to join InterAx’ Scientific Advisory Board?

During a visit at PSI, I had the opportunity to meet the scientific team of InterAx. I was impressed by the innovative nature of the biosensors developed by the team and by the potential of both the technology and InterAx’ scientists. The technology developed by InterAx is complementary to biosensor’s technology that I myself developed and I saw a great potential for synergy.

Where do you see the potential for InterAx’ technology?

The recent emergence of the concepts of GPCR functional selectivity and ligand-biased signaling applied to the discovery of more efficient and safer drugs targeting these receptors created a need for technologies probing the different activation modalities of the receptors. The biosensors developed by InterAx provide a new set of tools that will allow the identification of modalities associated with desired therapeutic outcomes.

How can your extensive knowledge and expertise help InterAx develop?

Given my long-standing expertise in GPCR signaling, I can advise InterAx’s scientists on the diverse aspects of GPCR signaling and their pharmacological modulation for therapeutic discovery. Based on my knowledge of the market’s need I will also help InterAx team prioritizing the value-added projects. I will also use my extended relationship network with academia and industry to identify possible collaborators and partners that could synergize with InterAx to reach their objectives.

JUL 2017

July 2017, Switzerland : We are nominated for the TOP 100 Swiss Startup Award 2017. A jury composed by professionals and your vote will rank the companies for the TOP 100 Swiss startups award. The profiles of the selected startups will be published in a special edition of the Handelszeitung, the most renown Swiss business and economy weekly newspaper.


FEB 2017

We welcome our new CSO Maria Waldhoer!


February 2017, Switzerland : Dr. Maria Waldhoer recently joined our team as Chief Scientific Officer. She has a track record of more than 20 years in GPCR / 7TM receptor signaling and pharmacology both in academia and industry. She brings in a wealth of expertise and knowledge in drug discovery for GPCRs.

DEC 2016

Seed financing round closed, undisclosed amount


December 2016, Switzerland / U.S. : InterAx Biotech AG has closed a seed financing round with a team of Boston based biotech investors.

NOV 2016

November 2016, Switzerland: The Swiss UpStart Challenge took a total of nine months and was divided into three phases. After each of the three phases, a selection round took place. InterAx reached the final round and won a prize worth CHF 20’000.- The Challenge, in collaboration with Fachhochschule Nordwestschweiz (FHNW), helped to successfully improve InterAx business case in a competitive environment.

OCT 2016

October 2016, Basel Switzerland: Each year, outstanding technology-based innovations and developments from start-ups, universities and technical institutions as well as established businesses are awarded prizes in three categories. InterAx, in the category Inventors, has convinced the jury during a pitch about its breakthrough in research and development and has therefore been nominated among the three finalists.


JUN 2016

6th place at >>venture>> Business Plan competition for InterAx!


June 2016, Zürich, Switzerland: InterAx made it with a 6th place among 119 Business Plans! »venture» is an initiative of the ETH Zurich, McKinsey & Company Switzerland, Knecht Holding, the innovation promotion agency CTI, and École Polytechnique Fédérale de Lausanne (EPFL). The leading Swiss-wide startup competition supports young entrepreneurs in founding a company.

FEB 2016

February 2016, Switzerland: A jury of entrepreneurs, investors, and scientists has selected InterAx Biotech out of eight projects as a winner of the Venture Kick Final, and a CHF 130,000 investment.

Commenting on the award, InterAx Biotech CEO Dr. Martin Ostermaier said, “Venture Kick was more than winning a price, it was a process in which our team was challenged and during which the business case continuously improved. It helped to expand our network of investors and advisors, and also to connect with other startups. The lessons learned were essential and brought us faster and more focused forward,”